BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mizuno S, Ono K, Mikami Y, Naganuma M, Fukuda T, Minami K, Masaoka T, Terada S, Yoshida T, Saigusa K, Hirahara N, Miyata H, Suda W, Hattori M, Kanai T. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res 2020;18:69-78. [PMID: 32013315 DOI: 10.5217/ir.2019.00084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ahmad A, Ansari MM, Mishra RK, Kumar A, Vyawahare A, Verma RK, Raza SS, Khan R. Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis. Materials Science and Engineering: C 2021;119:111582. [DOI: 10.1016/j.msec.2020.111582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
2 Suzuki K, Kakuta Y, Naito T, Takagawa T, Hanai H, Araki H, Sasaki Y, Sakuraba H, Sasaki M, Hisamatsu T, Motoya S, Matsumoto T, Onodera M, Ishiguro Y, Nakase H, Andoh A, Hiraoka S, Shinozaki M, Fujii T, Katsurada T, Kobayashi T, Fujiya M, Otsuka T, Oshima N, Suzuki Y, Sato Y, Hokari R, Noguchi M, Ohta Y, Matsuura M, Kawai Y, Tokunaga K, Nagasaki M, Kudo H, Minegishi N, Okamoto D, Shimoyama Y, Moroi R, Kuroha M, Shiga H, Li D, McGovern DPB, Kinouchi Y, Masamune A; MENDEL study group . Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab004. [PMID: 33501934 DOI: 10.1093/ibd/izab004] [Reference Citation Analysis]
3 Yoshimatsu Y, Mikami Y, Kanai T. Bacteriotherapy for inflammatory bowel disease. Inflamm Regen 2021;41:3. [PMID: 33441186 DOI: 10.1186/s41232-020-00153-4] [Reference Citation Analysis]
4 Matsumoto S, Mashima H. Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease. Sci Rep 2020;10:22176. [PMID: 33335169 DOI: 10.1038/s41598-020-79207-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Hiraoka S, Fujiwara A, Toyokawa T, Higashi R, Moritou Y, Takagi S, Matsueda K, Suzuki S, Miyaike J, Inokuchi T, Takahara M, Kato J, Okada H. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol 2021;36:137-43. [PMID: 32525567 DOI: 10.1111/jgh.15138] [Reference Citation Analysis]
6 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
7 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
8 Tsujii Y, Nishida T, Osugi N, Fujii Y, Sugimoto A, Nakamatsu D, Mukai K, Matsumoto K, Hayashi S, Yamamoto M, Nakajima S. Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study. Scand J Gastroenterol 2021;:1-7. [PMID: 34751626 DOI: 10.1080/00365521.2021.1998601] [Reference Citation Analysis]